Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of the total hip and lumbar spine at 18 months. Secondary outcomes will include group differences in bone mineral density (BMD) at the femoral neck, trochanter and wrist sites at 6, 12 and 18 months, spine and total hip bone mineral density (BMD) at 6 and 12 months and trabecular bone score (TBS) at 18 months. Secondary outcomes will also include within group changes from baseline for each of these variables. Bone turnover markers will also be measured to demonstrate that PINP levels will increase with administration of abaloparatide even in the setting of ongoing denosumab, while CTX levels will remain low.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

NCT00330460

Osteoporosis Osteopenia

COMPLETED PHASE3

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380

Osteoporosis

COMPLETED PHASE2

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

NCT00996801

Osteoporosis Postmenopausal Osteoporosis

COMPLETED PHASE2

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

NCT04936984

Osteoporosis

COMPLETED PHASE1

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

NCT04366726

Postmenopausal Osteoporosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Some women on denosumab treatment for osteoporosis remain at high risk for fracture. These include women who sustain incident fractures on denosumab and those who have declining bone mineral density (BMD) or persistently low bone mineral density (BMD), despite treatment. There are few options available for these patients. Denosumab withdrawal is associated with dramatic increased bone remodeling, rapid prominent bone loss, and multiple vertebral fractures (Cummings JBMR 2017). Switching from denosumab to teriparatide is associated with substantial BMD loss in the hip and femoral neck. After 2 years of denosumab treatment, when women are switched to teriparatide, total hip BMD remains below the baseline (at end of denosumab treatment) over the entire 2 years of teriparatide treatment (Leder Lancet 2015).

Abaloparatide might be a better option than teriparatide in patients switching from denosumab, because it is less pro-resorptive than teriparatide, however, hip BMD will still likely decline. Alternatively, adding abaloparatide to ongoing denosumab might be an excellent treatment option for these women. One of the investigators has previously shown that adding teriparatide to ongoing alendronate results in improved BMD and bone strength, compared to switching to teriparatide (Cosman JCEM 2009 and Cosman JBMR 2013). Others have shown that co-administration of teriparatide and denosumab to treatment naïve women increases BMD more than either agent alone (Tsai Lancet 2013, Leder et al JCEM 2014). Based on both of these observations, the investigators believe that adding abaloparatide to continued denosumab treatment will allow bone formation to increase, without increasing bone resorption (modeling-based bone formation) and will produce substantial BMD increments in both spine and hip.

Hypothesis: In women who still appear to be at high risk for fracture while receiving ongoing denosumab therapy, adding abaloparatide will increase BMD of the lumbar spine and total hip significantly more than continuing denosumab alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis, Postmenopausal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Denosumab alone

3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

Group Type ACTIVE_COMPARATOR

Denosumab Injection

Intervention Type DRUG

Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

Combination therapy

3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

Group Type ACTIVE_COMPARATOR

Denosumab Injection

Intervention Type DRUG

Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

Abaloparatide

Intervention Type DRUG

Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Denosumab Injection

Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

Intervention Type DRUG

Abaloparatide

Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prolia Tymlos

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* postmenopausal woman \>age 45 of any racial origin
* Participants will have received at least 4 prior denosumab treatments and be within 7 months from their last denosumab injection
* Participants are willing to participate for the duration of the study and have no physical or psychological illness that would prohibit them from participating.
* Diagnosis of osteoporosis based on bone mineral density and/or fracture criteria. Osteoporosis will be defined by bone mineral density T-Score \< -2.5 at lumbar spine (at least 2 evaluable vertebrae between L1 and L4), total hip or femoral neck. Osteoporosis will also be defined clinically in women with osteoporotic fractures within the preceding 5 years, including clinical vertebral or nonvertebral fractures or vertebral fracture confirmed by radiograph or lateral DXA VFA image, along with a DXA BMD T-Score \< -1.5 at one or more skeletal sites.

Exclusion Criteria

* Use of drugs other than denosumab (within the preceding 3 months) known to affect skeletal or calcium homeostasis.
* Fewer than 2 evaluable lumbar vertebrae
* A history of a symptomatic renal stone within the past 2 years or history of multiple symptomatic renal stones within the preceding 10 years
* Skeletal Disorders other than osteoporosis, including hypercalcemia, hyperparathyroidism, or Paget's Disease
* History of external or internal radiation therapy
* Estimated GFR below 30 ml/min
* Any contraindications to receipt of Abaloparatide or Denosumab
* History of any cancer in past 5 years (except basal/squamous skin cancer)
* Unexplained elevation of Serum Alkaline Phosphatase
* History of atypical femoral fracture

Minimum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes